Phase 1 Breakfree-1 data show sustained SLE activity reductions and 91% off immunosuppressants at month 12 after zola-cel.
Emily Littlejohn, DO, MPH
Advertisement
Emily Littlejohn, DO, MPH, is a lupus specialist at Cleveland Clinic. She is Co-Director of the Lupus Clinic, with specialty interests in general rheumatology, lupus, lupus disease activity measures, and women’s health in rheumatology.
Articles by Emily Littlejohn, DO, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
Selecting Sjögren’s Patients for Ianalumab and Weighing Safety
5